Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent EGFR and PIK3CA Mutations: A Case Report and Literature Review

Yonghui Wu,1,* Kai Zhang,1,* Jiexia Guan,2 Weibin Wu,1 Jian Zhang,1 Huiguo Chen1 1Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510630, People’s Republic of China; 2Department of Pathology, The Third Affiliated Hospital of...

Descripció completa

Dades bibliogràfiques

Autors principals:	Wu Y, Zhang K, Guan J, Wu W, Zhang J, Chen H
Format:	Artigo
Idioma:	Inglês
Publicat:	Dove Medical Press 2021-09-01
Col·lecció:	Cancer Management and Research
Matèries:	egfr mutation pik3ca mutation resistant mutation adenosquamous carcinoma anlotinib
Accés en línia:	https://www.dovepress.com/treatment-with-anlotinib-after-chemotherapy-and-egfr-tki-resistance-in-peer-reviewed-fulltext-article-CMAR
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!